CCC Diagnostics Inc Announces Expanded Insurance Coverage for the DirectHit Panel for Breast Cancer

Baltimore, MD, February 04, 2011 --(PR.com)-- CCC Diagnostics, Inc (CCCD), announced today that the Centers for Medicare & Medicaid will provide coverage for their Drug Response Indicator Test trademarked as the Breast Cancer DirectHitTM Test Panel for Breast Cancer. In addition to Medicare, CareFirst BlueCross/Blue Shield, WellPoint Unicare Networks, CMS Highmark Medicare Services and AmeriGroup will also provide coverage.

The DirectHit Panel analyzes an individual patient’s tumor in order to indicate the response to commonly prescribed anti-breast cancer chemotherapy drugs. DirectHit provides information about the tumor that may be used in addition to the usual tests to prescribe the most effective anticancer drug treatment.

John Hughes, CEO of CCC Diagnostics, commented “We are very pleased with the expanded coverage afforded DirectHit by the major health insurance providers. This expanded coverage will allow more patients to have access to DirectHit testing. Which is a significant step forward for physicians and their patients because the treatment will now have a higher probability of affecting the tumor.”

“No longer must one breast cancer treatment fit all,” says Mr. Hughes, “which should be welcome news for physicians and their patients.”

CCCD is a Baltimore, MD. based pharmacodiagnostics company, formed in 2004 by a core group of former Johns Hopkins University researchers. The company’s mission is to aid physicians in establishing a personalized treatment regime for individual cancer patients. CCCD is dedicated to “saving lives and life savings.” DirectHit™ is a trademark owned by CCCD. For more information about CCCD, please visit the company’s website at www.directhittest.com.

###